期刊
FRONTIERS IN NEUROLOGY
卷 14, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fneur.2023.1230889
关键词
spinal muscular atrophy; preterm; newborn screening; gene therapy; Zolgensma
Spinal muscular atrophy is a genetic disorder that causes progressive muscle weakness and atrophy. Early therapeutic interventions are important for improving survival and outcomes. This study discussed a case of a preterm infant with spinal muscular atrophy who received early treatment with novel therapies.
Spinal muscular atrophy (SMA) is a neuromuscular genetic disorder caused by the loss of lower motor neurons leading to progressive muscle weakness and atrophy. With the rise of novel therapies and early diagnosis on newborn screening (NBS), the natural history of SMA has been evolving. Earlier therapeutic interventions can modify disease outcomes and improve survival. The role of treatment in infants born preterm is an important question given the importance of early intervention. In this study, we discuss the case of an infant born at 32 weeks who was diagnosed with SMA on NBS and was treated with Spinraza (R) (Nusinersen) and Zolgensma (R) (Onasemnogene abeparvovec-xioi) within the first 2 months of life. With the scarce evidence that currently exists, clinicians should be aware of the efficacy and safety impact of early therapy particularly in the preterm infant.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据